Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 2/20 | 0.36 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.36 |
| ▸ | MYC | P01106 | 3/20 | 0.35 |
| ▸ | MAX | P61244 | 3/20 | 0.35 |
| ▸ | MKNK2 | Q9HBH9 | 3/20 | 0.35 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.34 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.34 |
| ▸ | EP300 | Q09472 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CLK1 | P49759 | 1/20 | 0.33 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.33 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.33 |
| ▸ | AR | P10275 | 1/20 | 0.33 |
| ▸ | PELP1 | Q8IZL8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1343153 | 0.92 | ALDH1A1 (0.36) | GCKGRM4MYCMAXMKNK2 | |
| SCHEMBL1342440 | 0.90 | MYC (0.35) | GRM4MYCMAXMKNK2PTPN1 | |
| SCHEMBL1340359 | 0.90 | MYC (0.37) | MYCMAXPTPN1EP300ALDH1A1 | |
| SCHEMBL1341860 | 0.89 | KMT2A (0.35) | GRM4MYCMAXALDH1A1CLK1 | |
| SCHEMBL2650118 | 0.89 | GCK (0.33) | GCKGRM4MKNK2 | |
| SCHEMBL1342890 | 0.88 | MYC (0.34) | GRM4MYCMAXMKNK2PTPN1 | |
| SCHEMBL1342969 | 0.84 | MEN1 (0.39) | ALDH1A1 | |
| SCHEMBL1343000 | 0.83 | GRM4 (0.39) | GCKGRM4 | |
| SCHEMBL1343007 | 0.83 | MAPT (0.38) | MYCMAXALDH1A1CLK1 | |
| SCHEMBL1343475 | 0.83 | GCK (0.42) | GCKMYCMAXMKNK2PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8063081-B2 | N-(2-Phenoxyphenyl)-N'-(thiazol-2-yl)urea; glucokinase inhibitor; antidiabetic, hypoglycemic agent; activators of glucokinase | NOVO NORDISK A/S (DK) | 2011-11-22 | — | — | US | disclosed |
| US-7897628-B2 | {2-[3-(4-Methyl-2-[2-methypropoxy]phenyl)-ureido]-thiazol-4-yl}-acetic acid ethyl ester; glucokinase inhibitor; antidiabetic, hypoglycemic agent; activators of glucokinase | NOVO NORDISK A/S (DK) | 2011-03-01 | — | — | US | disclosed |
| US-20040122235-A1 | Aryl carbonyl derivatives as therapeutic agents | VTV THERAPEUTICS LLC | 2004-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122235-A1 | Aryl carbonyl derivatives as therapeutic agents | GCK, GCKR, PDK2 | GCK 1/4885GRM4 2551/4885MYC 180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.